|
|
| | Ticlopidine hydrochloride Basic information |
| | Ticlopidine hydrochloride Chemical Properties |
| Melting point | 205°C | | density | 1.37 g/cm3 | | storage temp. | Inert atmosphere,Room Temperature | | solubility | Sparingly soluble in water and in anhydrous ethanol, very slightly soluble in ethyl acetate. | | pka | 7.64(at 25℃) | | form | Solid | | color | White | | Water Solubility | Soluble to 100 mM in water and to 100 mM in DMSO. | | λmax | 295nm(H2O)(lit.) | | Merck | 14,9421 | | InChI | InChI=1S/C14H14ClNS.ClH/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14;/h1-4,6,8H,5,7,9-10H2;1H | | InChIKey | MTKNGOHFNXIVOS-UHFFFAOYSA-N | | SMILES | C12C=CSC=1CCN(CC1C=CC=CC=1Cl)C2.Cl | | CAS DataBase Reference | 53885-35-1(CAS DataBase Reference) |
| Hazard Codes | Xn,Xi | | Risk Statements | 22-36/37/38 | | Safety Statements | 36-37/39-26 | | WGK Germany | 3 | | RTECS | XJ9089100 | | HS Code | 2934990002 | | Toxicity | LD50 in mice (mg/kg/24 hrs): 55 i.v.; >300 orally (Castaigne) |
| | Ticlopidine hydrochloride Usage And Synthesis |
| Chemical Properties | White Solid | | Originator | Ticlid,Millot,France,1978 | | Uses | Ticlopidine hydrochloride is a selective P2Y12 receptor antagonist. It inhibits ADP-induced platelet aggregation and displays antithrombotic activity following oral administration in vivo. | | Uses | An antithrombotic. a platelet aggregation inhibitor | | Uses | mucolytic, antibacterial, surface active agent | | Manufacturing Process | A solution of thieno[3,2-c]pyridine (13.5 g; 0.1 mol) and 2-chlorobenzyl
chloride (17.7 g) in acetonitrile (150 ml) is boiled during 4 hours.
After evaporation of the solvent, the solid residue consists of 5-(2-
chlorobenzyl)-thieno[3,2-c]pyridinium chloride which melts at 166°C
(derivative n° 30). This compound is taken up into a solution comprising
ethanol (300 ml) and water (100 ml). Sodium borohydride (NaBH4)(20 g) is
added portionwise to the solution maintained at room temperature. The
reaction medium is maintained under constant stirring during 12 hours and is
then evaporated. The residue is taken up into water and made acidic with
concentrated hydrochloric acid to destroy the excess reducing agent. The
mixture is then made alkaline with ammonia and extracted with ether. The
ether solution is washed with water, dried and evaporated. The oily residue is
dissolved in isopropanol (50 ml) and hydrochloric acid in ethanol solution is
then added thereto.
After filtration and recrystallization from ethanol, there are obtained 5-(2-
chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride crystals
(yield: 60%) having a melting point (Koefler block) of 190°C. | | Therapeutic Function | Platelet aggregation inhibitor | | Biological Activity | Selective P2Y 12 receptor antagonist. Inhibits ADP-induced platelet aggregation and displays antithrombotic activity following oral administration in vivo . | | References | [1] Chemical and Pharmaceutical Bulletin, 1994, vol. 42, # 8, p. 1676 - 1678
[2] Patent: CN105461735, 2016, A. Location in patent: Paragraph 0020; 0021
[3] Patent: CN105541862, 2016, A. Location in patent: Paragraph 0015; 0019 |
| | Ticlopidine hydrochloride Preparation Products And Raw materials |
|